ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) announced today the appointment of James M. Ford, MD, as Editor-in-Chief of the Society’s new journal, JCO Precision Oncology (JCO PO). Dr. Ford will set the scope and vision for the online-only journal, which will publish scientific and educational content that provides a deeper understanding of actionable cancer genomics.

JCO Precision Oncology will publish histology-independent, biomarker-integrated clinical cancer research in various article formats, including original research, reports, opinions, and reviews. Its aim is to advance the science and practice of precision oncology and define genomics-driven clinical care of patients with cancer. The first articles will be published by early 2017.

“We are elated to have Dr. Ford, a renowned leader in the field of cancer genomics, at the helm of our new journal,” said ASCO President Daniel F. Hayes, MD, FASCO. “JCO Precision Oncology represents a shift in the way cancer doctors are caring for their patients -- by tailoring treatments down to the specific genetic changes driving a tumor’s growth.”

Innovative and timely content will provide a deeper understanding of actionable cancer genomics, personalized translational and clinical oncology research, and recent treatment advances based on tumor molecular profiling. Publications will include all types of clinical research – from basket trials to exceptional response results – and extensive expert-driven commentary, editorials, and reviews considering the challenges and value of targeted therapies based on genomic analyses.

“Personalized treatment approaches allow us to glean valuable insights from each individual patient, creating a wealth of knowledge for us to build upon,” said Dr. Ford. “This journal provides an important learning platform for the oncology community, and it is a privilege to lead the effort to grow and share this exciting research.”
Dr. Ford is an Associate Professor of Medicine (Oncology), Pediatrics (Medical Genetics) and Genetics, and Director of the Stanford Cancer Genetics Clinic and the Cancer Genomics Program at the Stanford Cancer Institute. There, he performs next-generation tumor profiling to identify novel genetic targets for personalized targeted therapies. His research is dedicated to studying the genetic basis of breast and gastrointestinal cancer development, and the role of DNA repair in the treatment and prevention of cancer in families and populations.

With clinical interests in cancer genomics and the diagnosis and treatment of patients with a hereditary predisposition to cancer, Dr. Ford has published countless peer-reviewed articles focused on this area of research. He previously served as an editor for the journals *Cancer Research*, *PLoS Genetics*, and *DNA Repair*, and is on the Scientific Review Committee for the V Foundation for Cancer Research.

###

**About ASCO:**

Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at [www.ASCO.org](http://www.ASCO.org), explore patient education resources at [www.Cancer.Net](http://www.Cancer.Net), and follow us on [Facebook](http://Facebook), [Twitter](http://Twitter), [LinkedIn](http://LinkedIn), and [YouTube](http://YouTube).